Barclays PLC Valneva Se Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$9.88 - $13.82 $4,119 - $5,762	417 New	417 $4,000
Q2 2023 Aug 03, 2023	SELL	$9.45 - $16.98 $7,834 - $14,076	-829 Reduced 82.98%	170 $3,000
Q1 2023 May 04, 2023	SELL	$9.98 - $15.89 $6,816 - $10,852	-683 Reduced 40.61%	999 $10,000
Q4 2022 Feb 13, 2023	BUY	$10.38 - $14.87 $12,798 - $18,334	1,233 Added 274.61%	1,682 $21,000
Q3 2022 Nov 03, 2022	SELL	$9.8 - $23.35 $705 - $1,681	-72 Reduced 13.82%	449 $5,000
Q2 2022 Aug 12, 2022	SELL	$13.71 - $37.57 $4,250 - $11,646	-310 Reduced 37.3%	521 $12,000
Q1 2022 May 16, 2022	BUY	$27.0 - $50.99 $22,437 - $42,372	831 New	831 $28,000

683K

Ticker VALN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,103,504
Market Cap $386M
Description
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.